| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 18 | 2023 | 92 | 5.600 |
Why?
|
| Crohn Disease | 17 | 2022 | 63 | 4.180 |
Why?
|
| Colitis, Ulcerative | 15 | 2023 | 54 | 3.370 |
Why?
|
| Puerto Rico | 46 | 2021 | 1378 | 2.170 |
Why?
|
| Hepatitis C | 9 | 2015 | 125 | 1.650 |
Why?
|
| Liver Transplantation | 6 | 2016 | 30 | 1.600 |
Why?
|
| Cannabis | 2 | 2023 | 79 | 1.460 |
Why?
|
| Tissue and Organ Procurement | 3 | 2014 | 43 | 1.210 |
Why?
|
| Students, Medical | 4 | 2021 | 130 | 1.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 864 | 1.160 |
Why?
|
| Hepatitis C, Chronic | 6 | 2014 | 39 | 1.150 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 664 | 1.120 |
Why?
|
| Adult | 56 | 2023 | 11712 | 1.100 |
Why?
|
| Middle Aged | 53 | 2024 | 10129 | 1.090 |
Why?
|
| Liver Neoplasms | 5 | 2014 | 190 | 1.090 |
Why?
|
| Male | 65 | 2024 | 20025 | 1.080 |
Why?
|
| Female | 63 | 2024 | 20969 | 1.040 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2014 | 145 | 1.040 |
Why?
|
| Humans | 89 | 2024 | 37093 | 1.020 |
Why?
|
| Quality of Life | 5 | 2023 | 481 | 0.940 |
Why?
|
| Ostomy | 1 | 2023 | 2 | 0.910 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2021 | 9 | 0.900 |
Why?
|
| Prevalence | 16 | 2024 | 1455 | 0.880 |
Why?
|
| Ribavirin | 5 | 2014 | 18 | 0.870 |
Why?
|
| Hallucinogens | 1 | 2023 | 28 | 0.850 |
Why?
|
| Antiviral Agents | 6 | 2014 | 157 | 0.810 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 28 | 0.790 |
Why?
|
| Young Adult | 20 | 2022 | 4268 | 0.770 |
Why?
|
| Aged | 27 | 2024 | 6741 | 0.770 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 14 | 0.750 |
Why?
|
| Interferon-alpha | 4 | 2011 | 43 | 0.720 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 4 | 0.710 |
Why?
|
| Blood Component Removal | 1 | 2019 | 5 | 0.710 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 68 | 0.690 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 290 | 0.670 |
Why?
|
| Hypertension | 1 | 2024 | 796 | 0.570 |
Why?
|
| Risk Factors | 11 | 2024 | 3562 | 0.570 |
Why?
|
| Registries | 4 | 2014 | 335 | 0.560 |
Why?
|
| Polyethylene Glycols | 3 | 2014 | 84 | 0.550 |
Why?
|
| Tissue Donors | 3 | 2014 | 44 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 643 | 0.550 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 336 | 0.540 |
Why?
|
| Liver Cirrhosis | 4 | 2014 | 52 | 0.530 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 237 | 0.510 |
Why?
|
| Interleukins | 1 | 2014 | 29 | 0.500 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 767 | 0.440 |
Why?
|
| Managed Care Programs | 1 | 2013 | 38 | 0.430 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 151 | 0.430 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2011 | 7 | 0.420 |
Why?
|
| Attitude to Health | 2 | 2014 | 325 | 0.420 |
Why?
|
| Liver Failure | 2 | 2004 | 6 | 0.410 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2011 | 27 | 0.410 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 198 | 0.400 |
Why?
|
| Colonic Pouches | 2 | 2009 | 8 | 0.370 |
Why?
|
| Intestinal Fistula | 1 | 2010 | 4 | 0.360 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 19 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2022 | 2026 | 0.360 |
Why?
|
| Recombinant Proteins | 6 | 2014 | 515 | 0.350 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 21 | 0.350 |
Why?
|
| Immunologic Factors | 1 | 2010 | 45 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 628 | 0.340 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 76 | 0.330 |
Why?
|
| Psoriasis | 1 | 2008 | 17 | 0.330 |
Why?
|
| Public Health | 3 | 2015 | 372 | 0.330 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 34 | 0.330 |
Why?
|
| Organ Transplantation | 1 | 2008 | 18 | 0.320 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 172 | 0.320 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 2721 | 0.310 |
Why?
|
| Child | 8 | 2021 | 3131 | 0.310 |
Why?
|
| Abdominal Pain | 1 | 2008 | 24 | 0.310 |
Why?
|
| Adolescent | 14 | 2022 | 5363 | 0.310 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 494 | 0.300 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 186 | 0.300 |
Why?
|
| Weight Loss | 1 | 2008 | 131 | 0.290 |
Why?
|
| Smoking | 1 | 2012 | 940 | 0.260 |
Why?
|
| Health Facilities | 3 | 2011 | 27 | 0.250 |
Why?
|
| Liver Diseases | 3 | 2016 | 33 | 0.250 |
Why?
|
| Proctocolectomy, Restorative | 2 | 2001 | 19 | 0.250 |
Why?
|
| Receptors, Calcitriol | 2 | 2016 | 69 | 0.250 |
Why?
|
| HLA Antigens | 3 | 2021 | 20 | 0.250 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2004 | 1 | 0.250 |
Why?
|
| Health Surveys | 2 | 2020 | 373 | 0.240 |
Why?
|
| Public Assistance | 1 | 2004 | 27 | 0.240 |
Why?
|
| Medically Uninsured | 1 | 2004 | 56 | 0.230 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2379 | 0.230 |
Why?
|
| Genital Diseases, Female | 1 | 2023 | 37 | 0.230 |
Why?
|
| Ileostomy | 1 | 2023 | 6 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 148 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2024 | 1492 | 0.230 |
Why?
|
| Infertility | 1 | 2023 | 18 | 0.230 |
Why?
|
| Age Factors | 3 | 2020 | 1033 | 0.220 |
Why?
|
| Hermanski-Pudlak Syndrome | 1 | 2022 | 13 | 0.220 |
Why?
|
| Hemochromatosis | 2 | 1993 | 3 | 0.220 |
Why?
|
| Lipids | 2 | 2022 | 235 | 0.200 |
Why?
|
| Schistosomiasis mansoni | 1 | 2001 | 8 | 0.200 |
Why?
|
| Intestinal Mucosa | 2 | 2016 | 122 | 0.200 |
Why?
|
| Schistosoma mansoni | 1 | 2001 | 18 | 0.200 |
Why?
|
| HLA-DQ Antigens | 1 | 2021 | 6 | 0.200 |
Why?
|
| Age Distribution | 2 | 2020 | 225 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2023 | 1378 | 0.190 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2000 | 10 | 0.190 |
Why?
|
| Libido | 1 | 2020 | 6 | 0.190 |
Why?
|
| Osteotomy | 1 | 2020 | 4 | 0.190 |
Why?
|
| Genotype | 4 | 2021 | 730 | 0.190 |
Why?
|
| Gene Frequency | 3 | 2021 | 195 | 0.190 |
Why?
|
| Perception | 1 | 2021 | 195 | 0.180 |
Why?
|
| Alleles | 3 | 2021 | 321 | 0.180 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 23 | 0.170 |
Why?
|
| Health Care Reform | 1 | 1999 | 32 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2001 | 53 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 55 | 0.170 |
Why?
|
| Regression Analysis | 1 | 2020 | 455 | 0.170 |
Why?
|
| Analysis of Variance | 1 | 2020 | 550 | 0.170 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1998 | 1 | 0.160 |
Why?
|
| Budd-Chiari Syndrome | 1 | 1998 | 1 | 0.160 |
Why?
|
| Hepatitis, Autoimmune | 1 | 1998 | 2 | 0.160 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1998 | 4 | 0.160 |
Why?
|
| HIV Infections | 4 | 2010 | 2303 | 0.160 |
Why?
|
| Inflammation | 2 | 2022 | 618 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 276 | 0.160 |
Why?
|
| Hospitalization | 1 | 2022 | 388 | 0.160 |
Why?
|
| Hospitals, University | 4 | 2007 | 38 | 0.160 |
Why?
|
| Peptides | 1 | 2021 | 320 | 0.160 |
Why?
|
| Colon | 2 | 2016 | 103 | 0.140 |
Why?
|
| Probability | 2 | 2014 | 78 | 0.140 |
Why?
|
| Interferons | 2 | 2014 | 34 | 0.140 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1067 | 0.140 |
Why?
|
| Nocardia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Nocardia Infections | 1 | 2016 | 1 | 0.140 |
Why?
|
| Sexual Behavior | 2 | 2020 | 609 | 0.140 |
Why?
|
| Cholestasis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 893 | 0.130 |
Why?
|
| Time Factors | 4 | 2009 | 1742 | 0.130 |
Why?
|
| Academic Medical Centers | 3 | 2006 | 60 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2015 | 2 | 0.130 |
Why?
|
| Transglutaminases | 1 | 2015 | 8 | 0.130 |
Why?
|
| Linkage Disequilibrium | 2 | 2021 | 85 | 0.130 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 5 | 0.130 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2015 | 25 | 0.130 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 58 | 0.130 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2014 | 6 | 0.130 |
Why?
|
| Receptors, Interleukin | 1 | 2014 | 11 | 0.120 |
Why?
|
| Pouchitis | 2 | 2007 | 4 | 0.120 |
Why?
|
| GTP-Binding Proteins | 1 | 2015 | 60 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2014 | 36 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 105 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 113 | 0.120 |
Why?
|
| Prednisone | 2 | 1998 | 27 | 0.120 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1994 | 3 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1994 | 4 | 0.120 |
Why?
|
| Esophageal Motility Disorders | 1 | 1994 | 1 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 169 | 0.120 |
Why?
|
| Forecasting | 1 | 2014 | 128 | 0.120 |
Why?
|
| Survival Rate | 1 | 2014 | 311 | 0.120 |
Why?
|
| Esophagus | 1 | 1994 | 42 | 0.120 |
Why?
|
| Hepatitis B | 2 | 2011 | 38 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2014 | 57 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 196 | 0.110 |
Why?
|
| Infant | 2 | 2014 | 1046 | 0.110 |
Why?
|
| Government | 1 | 2013 | 6 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2011 | 1369 | 0.110 |
Why?
|
| Data Collection | 1 | 2013 | 194 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2022 | 484 | 0.110 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 26 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2014 | 1418 | 0.100 |
Why?
|
| Hepatitis C Antibodies | 2 | 2009 | 10 | 0.100 |
Why?
|
| Commerce | 1 | 2013 | 87 | 0.100 |
Why?
|
| Hepatitis B Vaccines | 1 | 2011 | 14 | 0.100 |
Why?
|
| Minority Groups | 3 | 2006 | 596 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 277 | 0.100 |
Why?
|
| Government Programs | 1 | 2011 | 29 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2011 | 90 | 0.090 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1990 | 1 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1991 | 36 | 0.090 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2010 | 12 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2010 | 16 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 104 | 0.090 |
Why?
|
| Biopsy, Needle | 3 | 1999 | 60 | 0.090 |
Why?
|
| Colonoscopy | 2 | 2008 | 104 | 0.090 |
Why?
|
| Phenytoin | 1 | 1989 | 2 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 974 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2010 | 56 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2009 | 325 | 0.090 |
Why?
|
| Hepatectomy | 1 | 2009 | 5 | 0.090 |
Why?
|
| United States | 6 | 2009 | 4223 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 441 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 108 | 0.080 |
Why?
|
| Duodenitis | 1 | 1988 | 2 | 0.080 |
Why?
|
| Peptic Ulcer | 1 | 1988 | 9 | 0.080 |
Why?
|
| Gastritis | 1 | 1988 | 11 | 0.080 |
Why?
|
| Risk | 1 | 2009 | 267 | 0.080 |
Why?
|
| Gastric Mucosa | 1 | 1988 | 51 | 0.080 |
Why?
|
| Phenotype | 2 | 2009 | 689 | 0.080 |
Why?
|
| Osteoarthritis | 1 | 1988 | 20 | 0.080 |
Why?
|
| Seroepidemiologic Studies | 4 | 2010 | 68 | 0.080 |
Why?
|
| Physician's Role | 1 | 2008 | 38 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1988 | 43 | 0.080 |
Why?
|
| Health Education | 1 | 2011 | 338 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 441 | 0.080 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 114 | 0.080 |
Why?
|
| Renal Dialysis | 1 | 2009 | 120 | 0.080 |
Why?
|
| Haplotypes | 2 | 2021 | 182 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2010 | 661 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1988 | 121 | 0.070 |
Why?
|
| Liver | 4 | 2016 | 479 | 0.070 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2007 | 18 | 0.070 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1986 | 1 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1130 | 0.070 |
Why?
|
| Biopsy | 3 | 2016 | 164 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2006 | 24 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2006 | 66 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2001 | 210 | 0.060 |
Why?
|
| Health Promotion | 1 | 2011 | 653 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2005 | 31 | 0.060 |
Why?
|
| Chordoma | 1 | 2004 | 1 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2004 | 1 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2004 | 18 | 0.060 |
Why?
|
| Iron | 3 | 2007 | 225 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2004 | 26 | 0.060 |
Why?
|
| Cultural Diversity | 1 | 2006 | 169 | 0.060 |
Why?
|
| Jejunal Neoplasms | 1 | 1984 | 1 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2004 | 214 | 0.060 |
Why?
|
| Mesenteric Arteries | 1 | 1984 | 20 | 0.060 |
Why?
|
| Anemia, Hemolytic | 1 | 2003 | 8 | 0.060 |
Why?
|
| Insurance Carriers | 1 | 2003 | 1 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 19 | 0.060 |
Why?
|
| Folic Acid | 1 | 2003 | 46 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 109 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2003 | 100 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 1999 | 217 | 0.050 |
Why?
|
| Latin America | 1 | 2022 | 45 | 0.050 |
Why?
|
| HIV-1 | 1 | 2008 | 706 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2022 | 69 | 0.050 |
Why?
|
| Vaccination | 1 | 2024 | 288 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 262 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 1984 | 251 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 803 | 0.050 |
Why?
|
| Antibodies, Helminth | 1 | 2001 | 23 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2005 | 451 | 0.050 |
Why?
|
| Algorithms | 1 | 2004 | 465 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 145 | 0.050 |
Why?
|
| Bone Density | 1 | 2000 | 75 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 325 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 448 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 481 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2001 | 174 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 560 | 0.040 |
Why?
|
| Echinococcosis, Hepatic | 1 | 1999 | 1 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2024 | 1207 | 0.040 |
Why?
|
| Recurrence | 2 | 2016 | 131 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 922 | 0.040 |
Why?
|
| Ileitis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 1998 | 7 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 1998 | 17 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 1998 | 8 | 0.040 |
Why?
|
| Ultrasonography | 1 | 1998 | 112 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 739 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 972 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 1998 | 78 | 0.040 |
Why?
|
| Ferritins | 2 | 1998 | 55 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1996 | 1 | 0.040 |
Why?
|
| Splenorenal Shunt, Surgical | 1 | 1996 | 1 | 0.040 |
Why?
|
| Sclerotherapy | 1 | 1996 | 3 | 0.040 |
Why?
|
| Propranolol | 1 | 1996 | 18 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 149 | 0.040 |
Why?
|
| Colonic Diseases | 2 | 2006 | 11 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 227 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2016 | 38 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 142 | 0.030 |
Why?
|
| Hemoglobins | 2 | 2007 | 107 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 260 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 104 | 0.030 |
Why?
|
| Esophageal Achalasia | 1 | 1994 | 1 | 0.030 |
Why?
|
| Peristalsis | 1 | 1994 | 1 | 0.030 |
Why?
|
| Heartburn | 1 | 1994 | 2 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 77 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 753 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 1994 | 19 | 0.030 |
Why?
|
| Chest Pain | 1 | 1994 | 37 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 1996 | 284 | 0.030 |
Why?
|
| Pregnancy | 1 | 1998 | 1549 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2012 | 8 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 333 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 928 | 0.030 |
Why?
|
| Bloodletting | 1 | 1991 | 1 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1990 | 37 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 127 | 0.020 |
Why?
|
| Hemolysis | 1 | 1990 | 40 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 146 | 0.020 |
Why?
|
| Meningioma | 1 | 1989 | 7 | 0.020 |
Why?
|
| Founder Effect | 1 | 2009 | 9 | 0.020 |
Why?
|
| France | 1 | 2009 | 17 | 0.020 |
Why?
|
| North America | 1 | 2009 | 67 | 0.020 |
Why?
|
| Seizures | 1 | 1989 | 68 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 208 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 130 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 1988 | 2 | 0.020 |
Why?
|
| Gastroscopy | 1 | 1988 | 7 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 61 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2008 | 26 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Markov Chains | 1 | 2008 | 35 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2001 | 583 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 1989 | 111 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2008 | 54 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2008 | 89 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2008 | 100 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 142 | 0.020 |
Why?
|
| Observer Variation | 1 | 2007 | 52 | 0.020 |
Why?
|
| Genome, Human | 1 | 2008 | 135 | 0.020 |
Why?
|
| Animals | 2 | 2001 | 15081 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 138 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 16 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 923 | 0.020 |
Why?
|
| Software | 1 | 2008 | 217 | 0.020 |
Why?
|
| Erythema Nodosum | 1 | 2006 | 2 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 2006 | 5 | 0.020 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 4 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 2006 | 3 | 0.020 |
Why?
|
| Uveitis | 1 | 2006 | 5 | 0.020 |
Why?
|
| Sacroiliac Joint | 1 | 2006 | 3 | 0.020 |
Why?
|
| Rectal Diseases | 1 | 2006 | 4 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 215 | 0.020 |
Why?
|
| School Admission Criteria | 1 | 2006 | 9 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 562 | 0.020 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1985 | 1 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 1985 | 4 | 0.020 |
Why?
|
| Body Piercing | 1 | 2005 | 2 | 0.020 |
Why?
|
| Tattooing | 1 | 2005 | 7 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2005 | 27 | 0.020 |
Why?
|
| Heroin Dependence | 1 | 2005 | 23 | 0.020 |
Why?
|
| Health Occupations | 1 | 2005 | 17 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2005 | 86 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 215 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 610 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2005 | 85 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2004 | 26 | 0.020 |
Why?
|
| Radiography | 1 | 1984 | 72 | 0.010 |
Why?
|
| Haptoglobins | 1 | 2003 | 10 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2007 | 935 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 225 | 0.010 |
Why?
|
| Mebendazole | 1 | 1999 | 4 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 8 | 0.010 |
Why?
|
| Anthelmintics | 1 | 1999 | 18 | 0.010 |
Why?
|
| Clinical Enzyme Tests | 1 | 1998 | 2 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1998 | 8 | 0.010 |
Why?
|
| Transaminases | 1 | 1998 | 8 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 50 | 0.010 |
Why?
|
| Sex Factors | 1 | 2001 | 898 | 0.010 |
Why?
|
| Cecal Diseases | 1 | 1985 | 2 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1985 | 103 | 0.000 |
Why?
|